Recombinant FVII in orthotopic liver transplantation (OLT): A preliminary single centre experience [5]

Intensive Care Medicine

Volumn 31, Issue 2, 2005, Pages 315-316

  De Gasperi, Andrea ^a   Baudo, Francesco ^b   De Carlis, Luciano ^b  

^a Ospedale Niguarda Ca Granda   (Italy)

^b OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; HUMAN; LETTER; LIVER TRANSPLANTATION; MORBIDITY; MORTALITY; RISK ASSESSMENT; THROMBOPLASTIN TIME;

BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; FACTOR VII; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 14944358504     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-004-2525-9     Document Type: Letter

References (5)

1. Key NS (2003) Recombinant Factor VIIa for intractable hemorrhage: more questions than answers. Transfusion 43:1649-1651
2. Kang YG (2000) Coagulopathy in hepatic disease. Liver Transpl 6:S72-75
3. Porte RJ, Molenaar IQ, Begliomini B, Groenland TH, Januszkiewicz A, Lindgren L, Palareti G, Hermans J, Terpstra OT (2000) Aprotinin for reducing blood loss and transfusion requirements in orthotopic liver transplantation: a multicentre, randomised, double-blind study. Lancet 355:1303
4. Hendriks HGD, Mejer K, De Wolf JT, Klompaker IJ, Porte RJ, de Kam PJ, Hagenaars AJ, Melsen T, Sloof MJ, van der Meer J (2001) Reduced transfusion requirements by recombinant Factor VIIa in orthotopic liver transplantation. Transplantation 71:402-405
5. Plasinich R, Testa G, Sucru Emre, Grande L, Candela, A, van der Meer JV, Porte R, Ghobrial RM, Isoniemi H, Schelde P, Erhardsen E, Klimtmalm G (2002) Safety and efficacy of single bolus dose of recombinant factor VIIa in patients undergoing orthotopic liver transplantation: a randomized multicenter trial (abstract). Hepatology 36:660